Geriatric Chorea

Clinics in Geriatric Medicine

Volumn 22, Issue 4, 2006, Pages 879-897

  Lorincz, Matthew T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHETAMINE DERIVATIVE; ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; BROMOCRIPTINE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LEVODOPA; METHAMPHETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; OPIATE; PERGOLIDE; PHENYTOIN; PRAMIPEXOLE; QUETIAPINE; REMACEMIDE; RESERPINE; RILUZOLE; RISPERIDONE; ROPINIROLE; TETRABENAZINE; TOXIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIPHOSPHOLIPID SYNDROME; APATHY; BALANCE DISORDER; BASAL GANGLION; CEREBROVASCULAR DISEASE; CHOREA; CREUTZFELDT JAKOB DISEASE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; GERIATRIC DISORDER; HUMAN; HUNTINGTON CHOREA; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOCALCEMIA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARANEOPLASTIC SYNDROME; PARKINSON DISEASE; PARKINSONISM; POLYCYTHEMIA VERA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

AGE FACTORS; AGED; CHOREA; HUMANS;

EID: 33748937591     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2006.06.005     Document Type: Review

References (88)

1. Albin R.L., Young A.B., and Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci 12 10 (1989) 366-375
2. Shoulson I. On chorea. Clin Neuropharmacol 9 Suppl 2 (1986) S85-S99
3. Dewey Jr. R.B., and Jankovic J. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol 46 8 (1989) 862-867
4. Garcia Ruiz P.J., Gomez-Tortosa E., del Barrio A., et al. Senile chorea: a multicenter prospective study. Acta Neurol Scand 95 3 (1997) 180-183
5. Warren J.D., Firgaira F., Thompson E.M., et al. The causes of sporadic and 'senile' chorea. Aust N Z J Med 28 4 (1998) 429-431
6. Piccolo I., Sterzi R., Thiella G., et al. Sporadic choreas: analysis of a general hospital series. Eur Neurol 41 3 (1999) 143-149
7. Piccolo I., Defanti C.A., Soliveri P., et al. Cause and course in a series of patients with sporadic chorea. J Neurol 250 4 (2003) 429-435
8. Ghika-Schmid F., Ghika J., Regli F., et al. Hyperkinetic movement disorders during and after acute stroke: the Lausanne Stroke Registry. J Neurol Sci 146 2 (1997) 109-116
9. Bhatia K.P., and Marsden C.D. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 117 Pt 4 (1994) 859-876
10. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 47 4 Suppl. 1 (2000) S2-S9 [discussion: S9-11]
11. Stacy M., Cardoso F., and Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 43 5 (1993) 937-941
12. Smith J.M., Oswald W.T., Kucharski L.T., et al. Tardive dyskinesia: age and sex differences in hospitalized schizophrenics. Psychopharmacology (Berl) 58 2 (1978) 207-211
13. Chouinard G., Annable L., Ross-Chouinard A., et al. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 8 4 Suppl (1988) 21S-26S
14. Goetz C.G., Chmura T.A., and Lanska D.J. History of movement disorders as a neurological specialty: Part 14 of the MDS-sponsored History of Movement Disorders exhibit, Barcelona, June 2000. Mov Disord 16 5 (2001) 954-959
15. Folstein S.E. Huntington's disease (1989), Johns Hopkins University Press, Baltimore (MD)
16. Nance M.A. Clinical aspects of CAG repeat diseases. Brain Pathol 7 3 (1997) 881-900
17. Robitaille Y., Lopes-Cendes I., Becher M., et al. The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol 7 3 (1997) 901-926
18. Gusella J.F., Wexler N.S., Conneally P.M., et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306 5940 (1983) 234-238
19. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 6 (1993) 971-983
20. Li S.H., Schilling G., Young III W.S., et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11 5 (1993) 985-993
21. Zoghbi H.Y., and Orr H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23 (2000) 217-247
22. Nakamura K., Jeong S.Y., Uchihara T., et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 10 14 (2001) 1441-1448
23. Cummings C.J., and Zoghbi H.Y. Trinucleotide repeats: mechanisms and pathophysiology. Annu Rev Genomics Hum Genet 1 (2000) 281-328
24. Luthi-Carter R., Strand A.D., Hanson S.A., et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 11 17 (2002) 1927-1937
25. American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. Laboratory guidelines for Huntington disease genetic testing. Am J Hum Genet 62 (1998) 1243-1247
26. Wexler N.S., Lorimer J., Porter J., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 101 10 (2004) 3498-3503
27. Goldberg Y.P., Kremer B., Andrew S.E., et al. Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. Nat Genet 5 2 (1993) 174-179
28. Langbehn D.R., Brinkman R.R., Falush D., et al. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 65 4 (2004) 267-277
29. Harjes P., and Wanker E.E. The hunt for Huntington function: interaction partners tell many different stories. Trends Biochem Sci 28 8 (2003) 425-433
30. Sugars K.L., and Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet 19 5 (2003) 233-238
31. Myers R.H., Sax D.S., Schoenfeld M., et al. Late onset of Huntington's disease. J Neurol Neurosurg Psychiatry 48 6 (1985) 530-534
32. Kremer B., Squitieri F., Telenius H., et al. Molecular analysis of late onset Huntington's disease. J Med Genet 30 12 (1993) 991-995
33. Young A.B., Shoulson I., Penney J.B., et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 36 2 (1986) 244-249
34. Penney Jr. J.B., Young A.B., Shoulson I., et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5 2 (1990) 93-99
35. Britton J.W., Uitti R.J., Ahlskog J.E., et al. Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease. Neurology 45 3 Pt 1 (1995) 443-447
36. Bamford K.A., Caine E.D., Kido D.K., et al. A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 45 10 (1995) 1867-1873
37. Bauer P., Laccone F., Rolfs A., et al. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington's disease-like phenotype. J Med Genet 41 3 (2004) 230-232
38. Fujigasaki H., Martin J.J., De Deyn P.P., et al. CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. Brain 124 Pt 10 (2001) 1939-1947
39. Ikeuchi T., Koide R., Tanaka H., et al. Dentatorubral-pallidoluysian atrophy: clinical features are closely related to unstable expansions of trinucleotide (CAG) repeat. Ann Neurol 37 6 (1995) 769-775
40. Warner T.T., Williams L.D., Walker R.W., et al. A clinical and molecular genetic study of dentatorubropallidoluysian atrophy in four European families. Ann Neurol 37 4 (1995) 452-459
41. Burke J.R., Wingfield M.S., Lewis K.E., et al. The Haw River syndrome: dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. Nat Genet 7 4 (1994) 521-524
42. Ikeuchi T., Onodera O., Oyake M., et al. Dentatorubral-pallidoluysian atrophy (DRPLA): close correlation of CAG repeat expansions with the wide spectrum of clinical presentations and prominent anticipation. Semin Cell Biol 6 1 (1995) 37-44
43. Komure O., Sano A., Nishino N., et al. DNA analysis in hereditary dentatorubral-pallidoluysian atrophy: correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology 45 1 (1995) 143-149
44. Rampoldi L., Danek A., and Monaco A.P. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med 80 8 (2002) 475-491
45. Danek A., Jung H.H., Melone M.A., et al. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci 229-230 (2005) 171-186
46. Grimes D.A., Lang A.E., and Bergeron C. Late onset chorea with typical pathology of Hallervorden-Spatz syndrome. J Neurol Neurosurg Psychiatry 69 (2006) 392-395
47. Holmes S.E., O'Hearn E., Rosenblatt A., et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet 29 4 (2001) 377-378
48. Marques-Dias M.J., Mercadante M.T., Tucker D., et al. Sydenham's chorea. Psychiatr Clin North Am 20 4 (1997) 809-820
49. Sanna G., Bertolaccini M.L., Cuadrado M.J., et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30 5 (2003) 985-992
50. Jennekens F.G., and Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatology (Oxford) 41 6 (2002) 605-618
51. Jennekens F.G., and Kater L. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41 6 (2002) 619-630
52. Cervera R., Asherson R.A., Font J., et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) 76 3 (1997) 203-212
53. Sanna G., Bertolaccini M.L., Cuadrado M.J., et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 42 2 (2003) 200-213
54. Toubi E., Khamashta M.A., Panarra A., et al. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 99 4 (1995) 397-401
55. Albin R.L., Bromberg M.B., Penney J.B., et al. Chorea and dystonia: a remote effect of carcinoma. Mov Disord 3 2 (1988) 162-169
56. Rogemond V., and Honnorat J. Anti-CV2 autoantibodies and paraneoplastic neurological syndromes. Clin Rev Allergy Immunol 19 1 (2000) 51-59
57. Yu Z., Kryzer T.J., Griesmann G.E., et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49 2 (2001) 146-154
58. Vernino S., Tuite P., Adler C.H., et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 51 5 (2002) 625-630
59. Shahar E., Shapiro M.S., and Shenkman L. Hyperthyroid-induced chorea. Case report and review of the literature. Isr J Med Sci 24 4-5 (1988) 264-266
60. Shaw P.J., Walls T.J., Newman P.K., et al. Hashimoto's encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers-report of 5 cases. Neurology 41 2 Pt 1 (1991) 228-233
61. Lin J.J., and Chang M.K. Hemiballism-hemichorea and non-ketotic hyperglycaemia. J Neurol Neurosurg Psychiatry 57 6 (1994) 748-750
62. Linazasoro G., Urtasun M., Poza J.J., et al. Generalized chorea induced by nonketotic hyperglycemia. Mov Disord 8 1 (1993) 119-120
63. Ahlskog J.E., Nishino H., Evidente V.G., et al. Persistent chorea triggered by hyperglycemic crisis in diabetics. Mov Disord 16 5 (2001) 890-898
64. Christiansen N.J., and Hansen P.F. Choreiform movements in hypoparathyroidism. N Engl J Med 287 11 (1972) 569-570
65. Janavs J.L., and Aminoff M.J. Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry 65 4 (1998) 436-445
66. Nath A., Hobson D.E., and Russell A. Movement disorders with cerebral toxoplasmosis and AIDS. Mov Disord 8 1 (1993) 107-112
67. Will R.G., Zeidler M., Stewart G.E., et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 47 5 (2000) 575-582
68. McKee D., and Talbot P. Chorea as a presenting feature of variant Creutzfeldt-Jakob disease. Mov Disord 18 7 (2003) 837-838
69. Prchal J.T. Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 17 5 (2003) 1151-1158 vi
70. Ania B.J., Suman V.J., Sobell J.L., et al. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol 47 2 (1994) 89-93
71. Bruyn G.W., and Padberg G. Chorea and polycythaemia. Eur Neurol 23 1 (1984) 26-33
72. Mas J.L., Gueguen B., Bouche P., et al. Chorea and polycythaemia. J Neurol 232 3 (1985) 169-171
73. Shinotoh H., Calne D.B., Snow B., et al. Normal CAG repeat length in the Huntington's disease gene in senile chorea. Neurology 44 11 (1994) 2183-2184
74. Friedman J.H., and Ambler M. A case of senile chorea. Mov Disord 5 3 (1990) 251-253
75. Murphy M.J. Clinical correlations of CT scan-detected calcifications of the basal ganglia. Ann Neurol 6 6 (1979) 507-511
76. Harrington M.G., Macpherson P., McIntosh W.B., et al. The significance of the incidental finding of basal ganglia calcification on computed tomography. J Neurol Neurosurg Psychiatry 44 12 (1981) 1168-1170
77. Forstl H., Krumm B., Eden S., et al. Neurological disorders in 166 patients with basal ganglia calcification: a statistical evaluation. J Neurol 239 1 (1992) 36-38
78. Manyam B.V., Bhatt M.H., Moore W.D., et al. Bilateral striopallidodentate calcinosis: cerebrospinal fluid, imaging, and electrophysiological studies. Ann Neurol 31 4 (1992) 379-384
79. Brannan T.S., Burger A.A., and Chaudhary M.Y. Bilateral basal ganglia calcifications visualised on CT scan. J Neurol Neurosurg Psychiatry 43 5 (1980) 403-406
80. Okada J., Takeuchi K., Ohkado M., et al. Familial basal ganglia calcifications visualized by computerized tomography. Acta Neurol Scand 64 4 (1981) 273-279
81. Illum F., and Dupont E. Prevalences of CT-detected calcification in the basal ganglia in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Neuroradiology 27 1 (1985) 32-37
82. Sachs C., Sjoberg H.E., and Ericson K. Basal ganglia calcifications on CT: relation to hypoparathyroidism. Neurology 32 7 (1982) 779-782
83. Lang A.E., and Marsden C.D. Alpha methylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 5 4 (1982) 375-387
84. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66 3 (2006) 366-372
85. Bonelli R.M., and Hofmann P. A review of the treatment options for Huntington's disease. Expert Opin Pharmacother 5 4 (2004) 767-776
86. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57 3 (2001) 397-404
87. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 61 11 (2003) 1551-1556
88. O'Suilleabhain P., and Dewey Jr. R.B. A randomized trial of amantadine in Huntington disease. Arch Neurol 60 7 (2003) 996-998